PER-145-08已完成未知
A Phase III Randomized, Double-blind, Placebo-controlled Study of Sorafenib as Adjuvant Treatment for Hepatocellular Carcinoma After Surgical Resection or Local Ablation.
BAYER S.A.,0 个研究点目标入组 0 人开始时间: 2009年2月5日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 100（—）
入选标准
- •Subjects who have undergone surgical resection or local ablation (PEI or percutaneous or intraoperative RFA) for treatment of HCC with curative intent within 4 months from staging to potentially curative treatment. A maximum of 2 local ablation courses may be administered during this time period.
- •At least 3 weeks (21 days) but no more than 7 weeks (49 days), from resection or last local ablation course, to CT/MRI scan date
- •Male or female subjects >/= 18 years of age
- •Confirmation of CR (absence of residual tumor after curative treatment), on the eligibility scan by independent radiological review.
- •For subjects undergoing surgical resection pathology proven complete removal of tumor.
- •Intermediate or High Risk of recurrence as assessed by tumor characteristics.
- •Child-Pugh score 5 -7 points. A Child-Pugh score of 7 points is allowed only in the absence of ascites.
- •ECOG Performance Status of 0.
- •Adequate bone marrow, liver and renal function
排除标准
- •Recurrent HCC
- •Child-Pugh score 7 points with presence of ascites.
- •Low risk of recurrence after curative treatment
- •History of cardiovascular disease
- •History of HIV infection
- •Active clinically serious infections (> grade 2 NCI-CTCAE version 3.0)
- •Subjects with seizure disorder requiring medication (such as steroids or anti-epileptics)
- •Subjects with evidence or history of bleeding diathesis
- •Subjects undergoing renal dialysis
- •Previous or concurrent cancer that is distinct in primary site or histology from the cancer being evaluated in this study EXCEPT cervical carcinoma in situ, treated basal cell carcinoma, superficial bladder tumors [Ta, Tis & T1] or any cancer curatively treated > 3 years prior to study entry as defined by the signing of informed consent..
- •Uncontrolled ascites (defined as not easily controlled with diuretic treatment)
- •Encephalopathy
- •History of GI bleeding within 30 days of randomization.
- •Subjects with a history of esophageal varices bleeding which has not been followed by effective therapy and/or treatment to prevent bleeding recurrence.
- •Prior anti cancer therapy for treatment of HCC (including sorafenib or any other molecular therapy) is excluded.
- •Major surgery within 4 weeks of start of study as defined by the signing of informed consent, except for surgical resection or local ablation of HCC.
- •Investigational drug therapy outside of this trial during or within 4 weeks of study entry, as defined by the signing of informed consent.
- •Liver transplantation, this includes patients on a transplant list with the intention to transplant
研究者
相似试验
未知
3 期
A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study of Subcutaneous Secukinumab in Prefilled Syringes to Demonstrate the Efficacy at 24 Weeks and to Assess the Long Term Efficacy, Safety, Tolerability and Usability up to 5 Years in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Anti-TNFalpha AgentsRheumatoid ArthritisJPRN-jRCT2080222045ovartis Pharma K.K.234
进行中（未招募）
1 期
Phase III Double-blind, Placebo-controlled Study of AZD1222 for thePrevention of COVID-19 in AdultsSARS-COV-2 infection (COVID-19)MedDRA version: 23.0Level: PTClassification code 10051905Term: Coronavirus infectionSystem Organ Class: 10021881 - Infections and infestationsEUCTR2020-005226-28-ITASTRAZENECA AB40,000
进行中（未招募）
1 期
Phase III, double-blinded study using AZD7442 or Placebo for the prevention of COVID-19 disease in adults who have not been exposed to COVID-19 infectioCOVID-19MedDRA version: 23.0Level: PTClassification code 10051905Term: Coronavirus infectionSystem Organ Class: 10021881 - Infections and infestationsEUCTR2020-004356-16-FRAstraZeneca AB5,000
进行中（未招募）
1 期
Phase 3, Double-blind, Placebo-controlled Study of AZD7442 for Treatment of COVID-19 in Outpatient AdultsCOVID-19 (Coronavirus Disease 2019)MedDRA version: 23.0Level: PTClassification code 10051905Term: Coronavirus infectionSystem Organ Class: 10021881 - Infections and infestationsEUCTR2020-005315-44-HUAstraZeneca AB1,700
进行中（未招募）
1 期
Phase 3, Double-blind, Placebo-controlled Study of AZD7442 for Treatment of COVID-19 in Outpatient AdultsCOVID-19 (Coronavirus Disease 2019)MedDRA version: 23.0Level: PTClassification code 10051905Term: Coronavirus infectionSystem Organ Class: 10021881 - Infections and infestationsEUCTR2020-005315-44-BGAstraZeneca AB1,700